27
Thu, Apr
22 New Articles

Scientists working at the European Molecular Biology Laboratory in Grenoble, France have developed a new technique that enables them to introduce up to 15 fluorescent markers to a mammalian cell in one go. They say their findings could help speed up drug development and screening.

Optimer Pharmaceuticals, Inc.announced that it has completed the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fidaxomicin to treat patients with Clostridium difficile infection (CDI) and to prevent recurrences of CDI. It is the most common cause of diarrhea in the hospital, and according to the CDC contributes to 15,000-30,000 deaths each year, a number that surpasses Methicillin-resistant Staphylococcus aureus (MRSA).

Amgen announced that it has won the Best New Drug awardfor Prolia(TM) (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

B. Braun,  In an effort to meet industry demands for expanded Cephalosporin offerings delivered to patients through safe and accurate administration, B. Braun Medical Inc. (B. Braun) announced that FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun Medical Inc.’s DUPLEX® Drug Delivery System will be available for purchase beginning today.

New data demonstrated that antibodies induced by Novartis Vaccines investigational, four component, Meningococcal Serogroup B Vaccine (4CMenB) killed the majority of a collection of geographically and genetically diverse meningococcal serogroup B (MenB) strains. The strain coverage research findings were recently published in the Proceedings of the National Academy of Sciences.

Cumberland Pharmaceuticals Inc. announced the publication of data affirming the safety and efficacy of Caldolor(R) (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults. Published in the peer-reviewed journal Critical Care, the study showed that IV ibuprofen was significantly more effective at reducing fever in hospitalized patients than placebo.

More Articles ...

Sign up via our free email subscription service to receive notifications when new information is available.
captcha